Skip to main content

rondecabtagene autoleucel

Generic: ronde-cel·Code: LYL314

rondecabtagene autoleucel: 2 clinical trials tracked.

rondecabtagene autoleucel evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about rondecabtagene autoleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

NCT07188558Registry updated 2026-08-04·Phase 3·LYEL
Recruiting

Primary endpoint: Event free survival

InterventionalRandomizedopen400 targetStarted 2026-01Completion 2032-0136 sites · United StatesLyell Immunopharma, Inc.

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT05826535Registry updated 2026-08-25·Phase 1/Phase 2·LYEL
Recruiting

Primary endpoint: Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent

Interventionalopen270 targetStarted 2023-05Completion 2031-0635 sites · Australia, United StatesLyell Immunopharma, Inc.